Table 3.
Survival comparison between patients with UTUC-BC and patients with primary bladder cancer.
| NMIBC (Stage 0–I) | MIBC (Stage II–III) | Metastatic cancer (Stage IV) | |||||
|---|---|---|---|---|---|---|---|
| UTUC-BC | Primary BC | UTUC-BC | Primary BC | UTUC-BC | Primary BC | ||
| Vital status | Alive | 283 (48.9) | 102,694 (67.1) | 10 (18.5) | 11,768 (37.0) | 0 (0.0) | 646 (11.3) |
| Deceased | 296 (51.1) | 50,394 (32.9) | 44 (81.5) | 20,002 (63.0) | 13 (100.0) | 5,084 (88.7) | |
| p value | <0.001* | 0.007* | 0.385 | ||||
| Cause of death | Bladder cancer | 70 (23.6) | 9,874 (19.4) | 27 (61.4) | 11,988 (60.0) | 6 (46.2) | 3,886 (76.4) |
| UTUC | 62 (20.9) | 589 (1.2) | 5 (11.4) | 140 (0.7) | 4 (30.8) | 56 (1.1) | |
| Other cancer | 57 (19.3) | 10,477 (20.8) | 7 (15.9) | 2,856 (14.3) | 0 (0.0) | 705 (13.9) | |
| Heart disease | 36 (12.2) | 10,514 (20.9) | 2 (4.5) | 1,750 (8.7) | 0 (0.0) | 149 (2.9) | |
| Other causes | 71 (24.0) | 19,529 (38.8) | 3 (6.8) | 3,268 (16.3) | 3 (23.1) | 288 (5.7) | |
| p value | <0.001* | <0.001* | <0.001* | ||||
| Overall survival probabilities (%) | 6-month survival | 93.4 (91.4–95.4) | 96.7 (96.7–96.8) | 77.4 (67.0–90.0) | 82.3 (81.9–82.8) | NA | 49.0 (47.7–50.3) |
| 1-year survival | 86.4 (83.6–89.2) | 93.6 (93.5–93.8) | 58.1 (46.1–73.1) | 68.1 (67.5–68.6) | NA | 28.1 (26.9–29.3) | |
| 3-year survival | 65.6 (61.6–70.0) | 81.8 (81.6–82.0) | 20.5 (11.6–36.0) | 43.2 (42.7–43.8) | NA | 8.0 (7.2–8.8) | |
| 5-year survival | 52.8 (48.5–57.5) | 71.4 (71.1–71.6) | 12.7 (5.8–28.2) | 34.2 (33.6–34.8) | NA | 5.0 (4.3–5.7) | |
| Median survival months (95% CI) | 67 (56–81) | 121 (119–122) | 17 (11–22) | 26 (26–27) | NA | 6 (6–7) | |
UTUC-BC, bladder recurrence after radical nephroureterectomy of upper urinary tract urothelial carcinoma; NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer; NA, not available. The bold values and
*
indicated that p < 0.05.